As a consequence, we rule out that cancer-specific neoexpression and compensation by other TCF/LEF family members account for expendability of TCF7L2 and suggest that this much more likely reflects far-reaching WNT/β-CATENIN pathway independence of CRC cell lines. The gene discussed is HNF4A; the disease is cancer.